Ehlers-Danlos Syndrome Clinical Trials and Treatments

Ehlers-Danlos syndrome (EDS) encompasses a group of genetic connective tissue disorders caused by mutations affecting collagen synthesis, structure, or processing. At least 13 subtypes are recognized, each with distinct genetic basis and clinical features. Classical EDS, which is less common than hypermobile EDS, usually results from type V collagen variants and features hyperextensible skin, joint hypermobility, poor wound healing, and characteristic skin texture (velvety or doughy).

The most common symptoms of Ehlers-Danlos Syndrome include Overly flexible joints (hypermobility) with dislocations, Hyperextensible, velvety skin with poor wound healing, Easy bruising and fragile tissues, Aortic and arterial aneurysms in vascular EDS, Gastrointestinal complications including perforations in vascular EDS, among others. At least 1 in 5,000 people overall (varies by subtype; vascular form much rarer at 1 in 250,000). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Ehlers-Danlos Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research into EDS is moving beyond symptom management toward targeted therapies designed specifically for different EDS subtypes. Researchers are actively working on pain management approaches, strategies to improve wound healing and reduce skin fragility, and molecular treatments tailored to the genetic basis of your specific type.

As of October 14, 2026, no current FDA drug label names Ehlers-Danlos Syndrome as a condition the drug treats.

Ehlers-Danlos Syndrome is caused by variants in any of many genes, most often COL5A1, COL5A2, COL3A1, COL1A1, COL1A2 and TNXB. At least 20 genes are known across the subtypes, but hypermobile EDS, the most common type, has no identified gene and remains a clinical diagnosis.

It follows autosomal dominant or recessive depending on type inheritance. At least 1 in 5,000 people overall (varies by subtype; vascular form much rarer at 1 in 250,000). A multigene panel identifies the cause in most families.

Yes. Ehlers-Danlos Syndrome can be caused by variants in many different genes (COL5A1, COL5A2, COL3A1, COL1A1, COL1A2 and TNXB are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. At least 20 genes are known across the subtypes, but hypermobile EDS, the most common type, has no identified gene and remains a clinical diagnosis.

It follows autosomal dominant or recessive depending on type inheritance.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Ehlers-Danlos Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Ehlers-Danlos Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.